Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Intravenous immunoglobulin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    449 result(s) found for: Intravenous immunoglobulin. Displaying page 6 of 23.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2009-013398-16 Sponsor Protocol Number: HULP-Nefro001 Start Date*: 2009-11-16
    Sponsor Name:Rafael Selgas
    Full Title: ACONDICIONAMIENTO DEL DONANTE CADÁVER MEDIANTE LA ADMINISTRACIÓN DE TIMOGLOBULINA PARA DISMINUIR EL ESTADO PRO-INFLAMATORIO TRAS LA MUERTE CEREBRAL
    Medical condition: Eficacia: Demostrar que la administración de timoglobulina en el donante cadáver reduce la expresividad antigénica del injerto, mediante una disminución de la expresión de marcadores de inflamación...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001413-42 Sponsor Protocol Number: MPD-RC 101 Start Date*: 2007-06-02
    Sponsor Name:AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE)
    Full Title: Study of Fludarabine based conditioning for Allogeneic Stem cell Transplantation for Myelofibrosis
    Medical condition: MYELOFIBROSIS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000855-14 Sponsor Protocol Number: 01-865-2005 Start Date*: 2005-07-18
    Sponsor Name:AZIENDA OSPEDALIERA DI PADOVA
    Full Title: Multicenter, not controlled, prospectic clinical phase IV study: safety and efficacy of an immunosuppressive regimen with Thymoglobuline and Rapamune in patients receiving a renal transplantation f...
    Medical condition: Acute rejection prophylaxis after single-double kidney transplantation from marginal donors making use of a not nephrotoxic immunosuppressive regimen.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10023439 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003200-40 Sponsor Protocol Number: NGAM-11 Start Date*: 2021-06-11
    Sponsor Name:Octapharma
    Full Title: Multicenter, Prospective, Parallel Group, Open-label, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating P...
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2014-002273-11 Sponsor Protocol Number: 54767414MMY3008 Start Date*: 2015-03-11
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for Hig...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) NL (Completed) GB (GB - no longer in EU/EEA) DK (Completed) IE (Completed) DE (Completed) BE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000928-37 Sponsor Protocol Number: 64007957MMY3006 Start Date*: 2023-02-15
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Mult...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003556-20 Sponsor Protocol Number: RH4131-03 Start Date*: 2014-02-19
    Sponsor Name:Dept. of Intensive Care 4131, Copenhagen University Hospital, Rigshospitalet
    Full Title: Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial
    Medical condition: Necrotizing Soft Tissue Infections
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10055648 Necrotizing fasciitis fungal LLT
    16.1 10021881 - Infections and infestations 10052892 Necrotising fasciitis fungal PT
    16.1 10021881 - Infections and infestations 10055647 Necrotizing fasciitis LLT
    16.1 10021881 - Infections and infestations 10055649 Necrotizing fasciitis staphylococcal LLT
    16.1 10021881 - Infections and infestations 10017068 Fournier's gangrene LLT
    16.1 10021881 - Infections and infestations 10028885 Necrotising fasciitis PT
    16.1 10021881 - Infections and infestations 10016229 Fasciitis necrotising LLT
    16.1 10021881 - Infections and infestations 10028886 Necrotising fasciitis NOS LLT
    16.1 10021881 - Infections and infestations 10028888 Necrotising fasciitis streptococcal PT
    16.1 10021881 - Infections and infestations 10028887 Necrotising fasciitis staphylococcal PT
    16.1 10021881 - Infections and infestations 10055650 Necrotizing fasciitis streptococcal LLT
    16.1 10021881 - Infections and infestations 10055643 Fasciitis necrotizing LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-002632-24 Sponsor Protocol Number: P160915 Start Date*: 2018-11-13
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Therapeutic plasma exchange, rituximab and intravenous immunoglobulins (IVIg) for severe acute exacerbation of idiopathic pulmonary fibrosis admitted in ICU: an open, randomized, controlled trial
    Medical condition: severe acute exacerbation of idiopathic pulmonary fibrosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005558-31 Sponsor Protocol Number: I10E-1306 Start Date*: 2015-01-08
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: International, multicentre, efficacy and safety study of I10E in the maintenance treatment of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM study I1...
    Medical condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Completed) IT (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000444-26 Sponsor Protocol Number: 17-BI-1206-02 Start Date*: 2018-05-02
    Sponsor Name:BioInvent International AB
    Full Title: Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractor...
    Medical condition: Indolent B-Cell Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Ongoing) PL (Prematurely Ended) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000263-27 Sponsor Protocol Number: IgPro10_4001 Start Date*: 2011-07-22
    Sponsor Name:CSL Behring LLC
    Full Title: An open-label, prospective, multicenter study to investigate the specificity of in vivo antibody binding to red blood cells in subjects with chronic immune thrombocytopenic purpura (ITP) treated wi...
    Medical condition: Chronic immune thrombocytopenic purpura (ITP)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10005329 - Blood and lymphatic system disorders 10021245 Idiopathic thrombocytopenic purpura PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-004498-29 Sponsor Protocol Number: 20190360 Start Date*: 2022-01-13
    Sponsor Name:Amgen Inc.
    Full Title: Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor...
    Medical condition: Newly Diagnosed Philadelphia (Ph)-negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002463-88 Sponsor Protocol Number: L00133 IV 301 (ORF) Start Date*: 2006-07-18
    Sponsor Name:Orfagen
    Full Title: Efficacy and safety of a human normal immunoglobulin product for intravenous administration (IVIg) in the treatment of dermatomyositis (DM) and polymyositis (PM): prospective, randomised, double-bl...
    Medical condition: Idiopathic DM and PM with insufficiently improved muscle strength under conventional therapy (Glucocorticosteroids associated with immunosuppressors).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-000211-24 Sponsor Protocol Number: IMAT-PV Start Date*: 2013-10-01
    Sponsor Name:Ruprecht-Karls-University Heidelberg
    Full Title: A multicenter, randomized, placebo-controlled, double-blind proof of concept study to evaluate the efficacy and safety of the human normal immunoglobulin Intratect® 5% for intravenous use as adjuva...
    Medical condition: patients with Pemphigus vulgaris
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001597-33 Sponsor Protocol Number: 20081203 Start Date*: 2009-06-18
    Sponsor Name:University Medical Center Utrecht
    Full Title: Development of chronic disease in newly diagnosed Idiopathic Thrombocytopenic Purpura of Childhood. A randomized controlled study on the influence of treatment with intravenous gammaglobulin on the...
    Medical condition: Acute Idiopathic Thrombocytopenic Purpura (ITP) in children
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10023095 ITP LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-009463-61 Sponsor Protocol Number: MD2009.01 Start Date*: 2009-08-06
    Sponsor Name:Sanquin Plasma Products
    Full Title: Controlled trail of immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial parvovirus B19 persistence - - a prospective, double-blind, randomized, placebo-controlled...
    Medical condition: PVB19 mediated cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056419 Dilated cardiomyopathy LLT
    9.1 10034099 Parvovirus B19 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-006520-19 Sponsor Protocol Number: MT103-202 Start Date*: 2007-10-11
    Sponsor Name:Amgen Research (Munich) GmbH
    Full Title: An open-label, multicenter phase II study to investigate the efficacy, safety, and tolerability of the bi-specific T-cell engager (BITE) MT103 in patients with minimal residual disease (MRD) of pos...
    Medical condition: Patients with minimal residual disease (MRD) of positive B-precursor acute lymphoblastic leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017707-28 Sponsor Protocol Number: LENDEXAL Start Date*: 2010-07-09
    Sponsor Name:Fundación Pethema
    Full Title: Ensayo multicéntrico, fase II de Lenalidomida, Ciclofosfamida y Dexametasona en pacientes con amiloidosis sistémica primaria (AL) de nuevo diagnóstico no candidatos a trasplante.
    Medical condition: Amiloidosis Sistémica Primaria
    Disease: Version SOC Term Classification Code Term Level
    11 10036673 Amiloidosis primaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001384-25 Sponsor Protocol Number: GMALL-BLIVEN Start Date*: 2021-09-28
    Sponsor Name:Goethe-Universität, vertreten durch den Präsidenten, dieser vertreten durch die LKP (bevollmächtigt durch den Sponsor)
    Full Title: An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL)
    Medical condition: Philadelphia negative, CD19-positive B-precursor acute lymphoblastic leukemia: -Refractory BCP-ALL to primary induction therapy -Untreated first relapse of BCP-ALL with first remission duration < 1...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066104 Precursor B-lymphoblastic leukaemia acute LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002698-36 Sponsor Protocol Number: MG0002 Start Date*: 2017-02-09
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects with Moderate to Se...
    Medical condition: Moderate to severe myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) CZ (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 13:33:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA